ESMO Colloquium: Recurrent glioblastoma management: Challenges and opportunities
30 Sep 2019
- Introduction (Matthias Preusser)
- Present standard of care for recurrent glioblastoma (Emilie Le Rhun)
- Novel systemic treatment approaches for recurrent glioblastoma (Matthias Preusser)
- Biology of CD95/Fas/CD95L (Michael Weller)
- CD95L/Fas ligand selective inhibition: Rationale and clinical results (Wolfgang Wick)
- Conclusions (Emilie Le Rhun)
This educational activity is provided by ESMO and supported by Apogenix.
View the ESMO colloquium details
ESMO Colloquium: Pancreatic cancer: Can better understanding of biology improve resectability and survival?
30 Sep 2019
- Introduction (Margaret Tempero)
- What have we achieved with recent medical approaches to improve survival (Thierry Conroy)
- How can surgery improve resectability criteria? (Massimo Falconi)
- What are the biological reasons for treatment resistance in pancreatic adenocarcinoma? (David Chang )
- What benefit can we expect from emerging targeted agents including ICI to improve survival? (Margaret Tempero)
- Conclusion (Margaret Tempero)
This educational activity is provided by ESMO and supported by Celgene.
View the ESMO colloquium details
ESMO Colloquium: Metastatic gastro-intestinal cancer: Multiple treatment lines, extended pipeline of available drugs and use of predictive markers.
How to best sequence the treatment proposal?
29 Sep 2019
- Introduction ( )
- Metastatic gastro-oesophageal adenocarcinoma (Salah-Eddin Al-Batran)
- Metastatic colorectal cancer (Michel Ducreux )
- Unresectable or relapsed hepato-cellular carcinomas (Jean-Luc Raoul )
- Conclusion ( )
This educational activity is provided by ESMO and supported by Lilly Oncology.
View the ESMO colloquium details
ESMO Colloquium: Relapsed/Refractory FLT3-ITD positive Acute Myeloid Leukemias (AML)
29 Sep 2019
- Introduction ( Jorge Cortes)
- Molecular profiling, prognosis and present Guidelines for Relapsed/Refractory AML (Lars Bullinger)
- Are FLT3 Mutated AML a special entity? (Gert Ossenkoppele)
- Recent results with FLT3 Inhibitors in FLT3-ITD positive Relapsed/Refractory AML and future development (Jorge Cortes )
- Conclusions (Jorge Cortes )
This educational activity is provided by ESMO and supported by Daiichi Sankyo Europe GmbH.
View the ESMO colloquium details
ESMO Colloquium: Metastatic clear cell renal cell carcinoma: How to navigate within multiple options and risk groups? What is the best sequence in a multi-line setting?
29 Sep 2019
- Introduction (Bernard Escudier)
- Present standard of care according to the 2019 ESMO Guidelines (Manuela Schmidinger)
- Comparative outcome in 1st line according to prognostic group and criteria for decision making (Camillo Guglielmo Porta)
- Options and criteria for treatment choice in 2nd and 3rd lines (Ronald de Wit)
- How to the sequence the use of drugs in a multi-lines’ strategy for RCC? (Bernard Escudier)
- Conclusions (Manuela Schmidinger)
This educational activity is provided by ESMO and supported by Ipsen.
View the ESMO colloquium details
ESMO Colloquium: Emerging biotherapy strategies in the treatment of solid tumours: Hope, Hype and Hurdles
28 Sep 2019
- Introduction (Laurence Albiges)
- Evolving role and practices changes with TKI in management of solid tumours ( )
- How far can immuno-oncology go on its own? (Ignacio Melero )
- TKI and immunotherapy combination: A cross-fire approach (Viktor Grünwald)
- Speaker panel discussion: Questions and answers
This educational activity is provided by ESMO and supported by Eisai Europe.
View the ESMO colloquium details
*Resources are not available.